Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation
International Journal of Molecular Sciences · 15.02.2023 · 24 (4) · 3861
DOI: 10.3390/ijms24043861 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2023. Verfasst von Stephan Nopp und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Atrial Fibrillation, MicroRNAs, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund FWF, Austrian Science Fund FWF with the Lise Meitner.
Abstract (Originalsprache)
The risk stratification of patients with atrial fibrillation (AF) for subsequent cardiovascular events could help in guiding prevention strategies. In this study, we aimed at investigating circulating microRNAs as prognostic biomarkers for major adverse cardiovascular events (MACE) in AF patients. We conducted a three-stage nested case–control study within the framework of a prospective registry, including 347 AF patients. First, total small RNA-sequencing was performed in 26 patients (13 cases with MACE) and the differential expression of microRNAs was analyzed. Seven candidate microRNAs with promising results in a subgroup analysis on cardiovascular death were selected and measured via using RT-qPCR in 97 patients (42 cases with cardiovascular death). To further validate our findings and investigate broader clinical applicability, we analyzed the same microRNAs in a subsequent nested case–control study of 102 patients (37 cases with early MACE) by using Cox regression. In the microRNA discovery cohort (n = 26), we detected 184 well-expressed microRNAs in circulation without overt differential expression between the cases and controls. A subgroup analysis on cardiovascular death revealed 26 microRNAs that were differentially expressed at a significance level < 0.05 (three of which with an FDR-adjusted p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
- Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333 Leiden, The Netherlands.
- Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
- Ludwig Boltzmann Institute for Cardiovascular Research, 1090 Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Stephan Nopp, Daniel Kraemmer, Cihan Ay, Anne Yaël Nossent
Förderung
- Austrian Science Fund FWF
- Austrian Science Fund FWF with the Lise Meitner
Zitieren
APA
Nopp, S., van der Bent, M. L., Kraemmer, D., Königsbrügge, O., Wojta, J., Pabinger, I., Ay, C., & Nossent, A. Y. (2023). Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation. International Journal of Molecular Sciences, 24(4), 3861. https://doi.org/10.3390/ijms24043861
Vancouver
Nopp S, van der Bent ML, Kraemmer D, Königsbrügge O, Wojta J, Pabinger I, et al. Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation. International Journal of Molecular Sciences. 2023;24(4):3861. doi:10.3390/ijms24043861
BibTeX
@article{Nopp2023,
author = {Nopp, Stephan and van der Bent, M Leontien and Kraemmer, Daniel and Königsbrügge, Oliver and Wojta, Johann and Pabinger, Ingrid and Ay, Cihan and Nossent, Anne Yaël},
title = {Circulatory miR-411-5p as a Novel Prognostic Biomarker for Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3861},
doi = {10.3390/ijms24043861}
}
EUVIMED